Effective symptomatic medication should be available in prophylactic trials in cluster headache

Headache

Volumn 51, Issue 2, 2011, Pages 307-

  Tfelt Hansen, Peer ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FROVATRIPTAN; SUMATRIPTAN; VERAPAMIL;

CLUSTER HEADACHE; EPISODIC CLUSTER HEADACHE; HUMAN; LETTER; MEDICAL SOCIETY; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CARBAZOLES; CLUSTER HEADACHE; GUIDELINES AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN RECEPTOR AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; TRYPTAMINES;

EID: 79551614334     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01832.x     Document Type: Letter

References (4)

1. Pageler L, Katsavara Z, Lampl C, et al. Frovatriptan for prophylactic treatment of cluster headache: Lessons for future trial design. Headache. 2011; 51: 129-134.
2. Lipton RB, Micieli G, Russell D, Solomon S, Tfelt-Hansen P, Waldenlind E,. International Headache Society Committee on Clinical Trials in Cluster Headache. First Edition. Guidelines for controlled trials of drugs in cluster headache. Cephalalgia. 1995; 15: 452-462.
3. The Sumatriptan Cluster Headache Study Group. Treatment for acute cluster headache with sumatriptan. N Engl J Med. 1991; 325: 322-326.
4. Leone M, D'Amico F, Frediani F, et al. Verapamil in the prophylaxis of episodic cluster headache: A double-blind study versus placebo. Neurology. 2000; 54: 1382-1385.